IMIC(SZ:000516) Sou Hu Cai Jing·2026-01-26 14:36Group 1 - The core viewpoint of the article highlights the financial performance and stock activity of Guo Ji Yi Xue (International Medicine), indicating a decline in revenue and profit for the third quarter of 2025 [2] - As of January 26, 2026, the stock price closed at 5.16 yuan, down 0.96%, with a turnover rate of 3.28% and a trading volume of 722,700 hands, amounting to a total transaction value of 373 million yuan [1] - The company reported a main revenue of 2.995 billion yuan for the first three quarters of 2025, a year-on-year decrease of 16.94%, and a net profit attributable to shareholders of -294 million yuan, down 38.45% year-on-year [2] Group 2 - In the third quarter of 2025, the company recorded a single-quarter main revenue of 961 million yuan, a year-on-year decline of 18.95%, and a net profit attributable to shareholders of -129 million yuan, a significant drop of 234.24% year-on-year [2] - The company has a debt ratio of 68.8%, with investment income of 20.7586 million yuan and financial expenses of 111 million yuan, resulting in a gross profit margin of 6.59% [2] - Over the past 90 days, two institutions have given a rating of "buy" for the stock, with an average target price of 5.5 yuan [3]